Next Phase Newsletter

A US-based advisory group also manages a seed fund making investments into healthcare companies. Traditionally, the firm has strong expertise in enterprise software and is most interested in healthcare companies that have a software component (such as EHR/EMR integration), monitoring technologies, and early-stage detection devices and diagnostics. The firm is also starting to explore opportunities in traditional biotech investments and drug discovery-enabling tools. The firm considers global opportunities. 

The firm is currently exploring opportunities in traditional life sciences (therapeutics, diagnostics) as well as software or technology-enabled healthcare companies. While the firm is opportunistic regarding specific technologies and disease areas, the firm generally does not invest in companies that require FDA regulatory approval. 

The firm does not have specific company or management team requirements and has no preference on leading or co-investing. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

The firm is an investment firm based in Shanghai, China. The firm manages 30 billion RMB and invests in fund of funds as well as direct equity investments. The firm invests across multiple sectors, with life science and healthcare being one of its primary focuses. The sweet spot starts from pre-A rounds, and the firm can invest anywhere up to pre-IPO stages. While the firm primarily focuses on opportunities in China, it is open to global opportunities, particularly those interested in soft-landing in China/Shanghai or with a China angle. The firm is open to both leading investments and co-investing. 

Within life science and healthcare, the firm is most interested in biotech therapeutics and medical technologies. For therapeutics, the firm is open to exploring various modalities (excluding mRNA) and indications such as CNS and oncology. For medical devices, the firm seeks innovative technologies, including invasive technologies, imaging devices, and brain-computer interfaces, rather than non-innovative solutions such as consumables. 

The firm does not have specific requirements for a company’s founding team but prefers companies interested in coming to Shanghai/China. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A multi-stage generalist venture capital investor can write flexible check sizes typically up to $300,000 for early-stage opportunities and can participate in follow-on investments. The firm is open to global companies. 

The firm has invested in digital health, techbio, value-based healthcare, and life sciences. The firm is disease-agnostic. Notable investments in healthcare have included digital health platforms, pharmacy solutions, clinical trial innovation, and biotech companies. 

The firm does not have specific company or management team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A China-based venture capital investor manages seven USD funds with limited partners from prestigious academic institutions and hospital systems in the United States. The firm is capable of investing at any stage, from seed to pre-IPO. While the firm manages USD funds, it is rooted in China and is particularly interested in opportunities with a China angle or involving Asian founders. 

The firm has previously invested at the intersection of AI and healthcare, such as AI-driven drug discovery, diagnostics, and imaging, but has broadened its scope to include therapeutics. The firm is particularly interested in novel modalities, including drug conjugates, radiopharmaceuticals, and cell and gene therapies. The firm is open to various indications, prioritizing those with considerable market potential, such as oncology, immunology, CNS, pain management, and kidney diseases. In terms of development phases, the firm prefers companies from IND to clinical phases but is willing to consider companies in the PCC phase at the earliest. 

The firm prefers companies with strong management teams, particularly those with industry experience in pharma or biotech. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

The firm is a venture capital investor headquartered in the US. The firm is currently investing from its third fund and allocates half of its capital into life science investments. The firm invests in Seed and Series A stages, with a typical check size of $1 million and up to $3 million in total after follow-on investments. The firm invests in four to five new companies each year and focuses on opportunities within the United States. 

The firm invests primarily in therapeutics and is also open to medical devices, molecular-based diagnostics, and digital health. The firm is indication- and modality-agnostic. 

The firm has no specific management team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

A venture capital investor makes equity investments ranging from a few hundred thousand dollars to $3 million, with additional capital reserved for follow-on rounds. The firm is seeking companies located throughout the United States and plans to make two to three new investments over the next 9–12 months. The firm invests in both seed-stage and later-stage companies. 

The firm is interested in companies developing medical devices and diagnostics, healthcare IT products, and life science research tools, with an emphasis on fast-to-market, low-capital-intensity products that reduce the cost of delivering quality healthcare. The firm is open to all sub-sectors and indications in the medical technology space, except for those targeting diseases and disorders of the spine. 

The firm seeks companies with skilled and experienced management teams. The firm generally takes a board seat after investment and plays an active role in the management. The firm is willing to invest in both public and privately held companies. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology

This venture capital firm invests in pre-seed to seed stage opportunities with initial check sizes ranging from $500k to $1M and maintains reserves for follow-on capital. While the firm prefers to lead deals, it is open to syndication. Investment geography spans both Europe and the United States. 
 

The investment team has a deep technical background in software, artificial intelligence, and algorithms. Within life sciences and healthcare, the firm is focused on techbio, synthetic biology, computational biology, chemistry & materials. 

The firm is also open to hardware (e.g., diagnostics or medical devices) that enable novel data modalities, digital health, and therapeutic platforms. 

However, the firm does not invest in traditional therapeutic assets and is indication-agnostic. Opportunities can be considered as early as the pre-prototype stage, provided there is a roadmap toward intellectual property or patent protection. 

There are no strict team or company prerequisites, though the firm has a preference for technical founders with strong scientific grounding. The firm may take a board or observer seat depending on the opportunity. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Tags: business, finance, health, investing, technology